Eli Lilly Achieves Strong Financial Results in Q3 2025
Eli Lilly and Company (NYSE: LLY) has reported significant financial growth for the third quarter of 2025, reflecting a robust demand for its leading products and a notable increase in pipeline development activities.
Impressive Revenue and Earnings Growth
In Q3 2025, Lilly achieved a remarkable revenue increase of 54%, totaling $17.60 billion, driven largely by the strong market performance of Mounjaro and Zepbound. The company's earnings per share (EPS) also surged, rising from $1.07 in the prior year to $6.21 on a reported basis and up to $7.02 on a non-GAAP basis, marking growth of $5.14 and $5.84, respectively.
Upscaled Financial Projections
Given the robust performance, Lilly has raised its 2025 financial guidance. The company now projects full-year revenues between $63.0 billion and $63.5 billion. Additionally, it has upgraded its EPS guidance to a range of $21.80 to $22.50 for reported figures and to $23.00 to $23.70 on a non-GAAP basis.
Advancements in R&D Pipeline
Lilly's R&D pipeline also displayed significant momentum in Q3 2025. The company's promising drug, orforglipron, which targets type 2 diabetes and obesity, continued to show positive outcomes in four Phase 3 trials. These results have positioned Lilly to submit for regulatory approvals by year-end, reflecting their commitment to tackling the obesity epidemic.
Regulatory Successes and Manufacturing Expansion
Among Lilly's regulatory advancements is the recent approval of Inluriyo (imlunestrant) by the U.S. FDA for adults battling advanced breast cancer. Meanwhile, Lilly is expanding its manufacturing capabilities by establishing new facilities in Virginia and Texas and enhancing operations at its Puerto Rico site. This expansion is expected to bolster the production of their burgeoning product line.
Key Product Revenue Highlights
Lilly’s success can be attributed to its key products. Mounjaro notably generated $6.52 billion in revenue, reflecting a striking 109% increase from the previous year. U.S. sales reached $3.55 billion, while international sales substantially increased due to rising demand.
Zepbound also performed impressively, with U.S. revenues climbing 184% to $3.57 billion, thanks to growing market interest. Verzenio continued to show resilience in the competitive oncology space, generating $1.47 billion in revenue worldwide.
Research and Development Investment
Investment in research and development remains a priority for Lilly, with expenses rising 27% to $3.47 billion, accounting for nearly 19.7% of total revenue. This reflects the company’s dedication to innovating and expanding its therapeutic offerings.
Marketing, selling, and administrative expenses also saw an increase of 31%, evidencing Lilly’s commitment to supporting both current and future product launches.
Market Outlook and Future Guidance
With a favorable market response to Mounjaro and Zepbound, the outlook for Lilly appears strong as it moves forward. The company remains unwavering in its mission to enhance life through science and innovation, guided by its newly revised financial targets.
Frequently Asked Questions
What drove Eli Lilly's revenue growth in Q3 2025?
The primary drivers were the substantial sales of Mounjaro and Zepbound, alongside strong volume growth across its key products.
What is the EPS guidance for Lilly for 2025?
Lilly has raised its EPS guidance to a range of $21.80 to $22.50 on a reported basis and $23.00 to $23.70 on a non-GAAP basis.
What recent regulatory approvals has Lilly received?
Lilly received FDA approval for Inluriyo, targeting advanced breast cancer patients, and will likely submit for orforglipron’s approval for obesity treatment by the year’s end.
How much did Lilly invest in R&D?
In Q3 2025, Lilly’s R&D expenses surged to $3.47 billion, underscoring its commitment to innovation and product development.
What expansions has Lilly undertaken in its manufacturing capabilities?
Lilly announced plans to build new manufacturing facilities in Virginia and Texas, as well as expand its site in Puerto Rico to enhance production capacity.
